Results 261 to 270 of about 69,107 (331)

The difference in type 2 diabetes care between the National Health Insurance beneficiaries and public assistance recipients in Japan: A retrospective cohort study based on claims data in a municipality

Journal of Diabetes Investigation, Volume 17, Issue 2, Page 347-359, February 2026.
We examined the differences in type 2 diabetes care between public assistance recipients and National Health Insurance beneficiaries in Japan by using claims data from a municipality. Public assistance might improve diabetes care process, but not fully health outcomes.
Takuya Yamaoka, Takehiro Sugiyama, Daisuke Nishioka, Naoki Kondo, Nanako Tamiya   +4 more
wiley   +1 more source

PARP inhibitor-induced anti-tumour chemokine response is suppressed by dipeptidyl peptidase 4 (DPP4) in ovarian cancer. [PDF]

Br J Cancer
Stange C, Dreyer TF, Riedel M, Elsen F, Seitz S, Hamann D, Kiechle M, Bronger H.   +7 more
europepmc   +1 more source

Predictors of glycemic control with imeglimin for type 2 diabetes: Results of machine learning analyses using clinical trial data

Journal of Diabetes Investigation, Volume 17, Issue 2, Page 214-226, February 2026.
Identifying patient characteristics predictive of treatment response is crucial for optimizing type 2 diabetes outcomes. Using data from three phase 2/3 imeglimin trials in Japan, this analysis applied machine learning to determine characteristics associated with HbA1c improvement.
Katsuhiko Hagi, Kazumasa Yoshida, Hirotaka Watada, Kohei Kaku, Kohjiro Ueki   +4 more
wiley   +1 more source

Use of dipeptidyl peptidase-4 inhibitors is associated with lower risk of severe renal outcomes in pre-dialysis patients with Type 2 diabetes. [PDF]

J Intern Med
Hung TY, Lin TC, Liou YJ, Lin TH, Hsu YJ, Lin LY, Wang MT.   +6 more
europepmc   +1 more source

Comparison of the Efficacy of Dipeptidyl Peptidase-4 Inhibitors and Sodium-Glucose Cotransporter-2 Inhibitors in Diabetic Patients with Steatotic Liver Disease. [PDF]

Gut Liver
Ko Y, Hur MH, Park Y, Park J, Shin H, Lee YB, Cho EJ, Lee JH, Yu SJ, Yoon JH, Kim YJ.   +10 more
europepmc   +1 more source

Association of Dipeptidyl Peptidase-4 Inhibitors with Glaucoma Risk in Patients with Type 2 Diabetes: A Nationwide Cohort Study. [PDF]

Ophthalmol Sci
Lu YA, Tien PT, Cheng YD, Hsieh YW, Cho DY, Tsai SF, Weng CH, Lin HJ, Lin HJ, Wang IJ, Chou CC.   +10 more
europepmc   +1 more source

Effect of Beta-Cell Function on Glucose Variability When Switching From Insulin Degludec Plus a Dipeptidyl Peptidase-4 Inhibitor to Insulin Degludec/Liraglutide: Preliminary Results From a Pilot Study. [PDF]

Int J Endocrinol
Oe Y, Nomoto H, Nakamura A, Kuwabara S, Takahashi Y, Yasui A, Izumihara R, Miya A, Kameda H, Cho KY, Atsumi T.   +10 more
europepmc   +1 more source

Dipeptidyl Peptidase 4 (DPP4) Exacerbates Osteoarthritis Progression in an Enzyme-Independent Manner. [PDF]

Adv Sci (Weinh)
Li X, Zhang Z, Jiang W, Ju Y, Guo W, Huang Z.   +5 more
europepmc   +1 more source

Dipeptidyl peptidase-4 deficiency prevents chronic stress-induced cardiac remodeling and dysfunction in mice. [PDF]

FASEB J
Jiang Z, Zhao L, Xin M, Wan Y, Xu S, Yue X, Jin X, Cui R, Li Y, Kim W, Wu H, Cheng XW.   +11 more
europepmc   +1 more source